New hope for hard-to-treat ovarian cancer: drug duo shows promise in early trial
NCT ID NCT07314619
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests a combination of two drugs (sacituzumab tirumotecan and bevacizumab) in 30 women with platinum-resistant recurrent ovarian cancer, a type that is very hard to treat. The goal is to see if the combo can shrink tumors better than current options. Participants must have had 1-3 prior treatments and be at least 18 years old.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PLATINUM-RESISTANT RECURRENT OVARIAN CANCER (PROC) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
The First Affiliated Hospital of Zhengzhou University
Zhengzhou, Henan, 450000, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.